All In Biotech

Drug Trial Radar · NCT04667377

A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight

A Phase II, Randomized, Double Blind, Parallel Group,46 Weeks Dose-finding Study of BI 456906 Administered Once Weekly Subcutaneously Compared With Placebo in Patients With Obesity or Overweight

Last checked: Nov 19, 2026Latest source record: Nov 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 387 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

387

Actual

Start

Mar 8, 2021

Primary completion

Sep 15, 2022

Study completion Oct 7, 2022

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Dec 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults, aged 18 to 75 years, with overweight or obesity. People with body mass index (BMI) of 27 or higher to join the study. People who have diabetes cannot participate. The purpose of this study is to find out whether a medicine called BI 456906 helps people lose weight. Participants are put into 5 groups by chance. 4 groups get different doses of BI 456906. The fifth group gets placebo. Participants get BI 456906 or placebo as injections under the skin once a week. Placebo injections look like BI 456906 injections but do not contain any medicine. Participants are in the study for about a year. During this time, there are about 20 in-person visits to the study site. At the study site visits, doctors measure participants' body weight. Results are compared between the BI 456906 groups and the placebo group. The doctors also regularly check the general health of the participants.

Conditions

  • Obesity

Interventions

  • BI 456906Drug

    BI 456906

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change in Body Weight From Baseline to Week 46Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46.

Locations

43 sites in 12 countries. Site status is shown where the registry gives one.

  • Diablo Clinical Research

    Walnut Creek, California

  • L-MARC Research Center

    Louisville, Kentucky

  • Lucas Research, Inc.

    Morehead City, North Carolina

  • PMG Research of Wilmington, LLC

    Wilmington, North Carolina

  • Valley Weight Loss Clinic

    Fargo, North Dakota

  • Velocity Clinical Research, Inc.

    Cleveland, Ohio

  • TLM Medical Services, LLC

    Columbia, South Carolina

  • Coastal Carolina Research Center

    North Charleston, South Carolina

  • Washington Center for Weight Management and Research, Inc.

    Arlington, Virginia

  • Allegiance Research Specialists

    Wauwatosa, Wisconsin

  • The Boden Initiative

    Camperdown, New South Wales, Australia

  • Nepean Hospital

    Kingswood, New South Wales, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Eastern Clinical Research Unit

    East Ringwood, Victoria, Australia

  • Austin Health

    Heidelberg, Victoria, Australia

  • UZ Leuven

    Leuven, Belgium

  • Joanne F Liutkus Medicine Professional Corporation

    Cambridge, Ontario, Canada

  • Bluewater Clinical Research

    Sarnia, Ontario, Canada

  • Canadian Phase Onward Inc.

    Toronto, Ontario, Canada

  • LMC Clinical Research Inc. (Bayview)

    Toronto, Ontario, Canada

  • Recherche GCP Research

    Montreal, Quebec, Canada

  • Beijing Chao-Yang Hospital

    Beijing, China

  • Beijing Luhe Hospital Capital Medical University

    Beijing, China

  • The First Hospital of Jilin University

    Changchun, China

  • Wuhan Union Hospital

    Wuhan, China

  • Klinische Forschung Berlin GbR

    Berlin, Germany

  • Universitätsklinikum Carl Gustav Carus Dresden

    Dresden, Germany

  • EB Flevoresearch

    Almere Stad, Netherlands

  • PT & R

    Beek, Netherlands

  • Franciscus Gasthuis

    Rotterdam, Netherlands

  • Albert SchweitzerZiekenhuis

    Zwijndrecht, Netherlands

  • Optimal Clinical Trials

    Auckland, New Zealand

  • P3 Research

    Newtown Wellington NZ, New Zealand

  • Salvia Lekston I Madej Sp. J.

    Katowice, Poland

  • Metabolic Health Center Pawel Bogdanski

    Poznan, Poland

  • Seoul National University Bundang Hospital

    Seongnam, South Korea

  • Kyung Hee University Hospital at Gangdong

    Seoul, South Korea

  • The Catholic University of Korea, Yeouido St.Mary's Hospital

    Seoul, South Korea

  • Ladulaas Kliniska Studier

    Borås, Sweden

  • Forskningsenheten Carlanderska

    Gothenburg, Sweden

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.